prostate cancer

Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.

This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.

The University of Texas Southwestern professor’s research focused on the androgen hormones that cause male sexual differentiation and may also lead to prostate disease.

Good girl, Florin!

In a proof-of-concept study, researchers used dogs’ diagnoses of prostate cancer to inform a machine learning algorithm with the goal of one day detecting cancers with canine-level accuracy.

Through his studies on cancer-causing viruses, the University of California, Los Angeles, professor has helped develop lifesaving treatments.

Donald Coffey, a longtime professor at Johns Hopkins University, discovered the nuclear matrix within cells and its role in DNA replication.

The proteins drebin and EB3 are part of a “homing pathway” that helps cancer cells move from the prostate into the bloodstream or lymphatic system.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

Researchers construct a 3-D cell model of the prostate gland and use it to show that BPA exposure may increase the risk of cancer in the organ.

Charles Sawyers, who began his research career just as the genetic details of human oncogenes were emerging, codeveloped Gleevec, the quintessential targeted cancer therapy.

Diet, exercise, and stress management may lengthen telomeres, a new study shows, though some scientists are skeptical.

Nerves growing in cancerous prostate glands appear to spur disease progression.

Researchers have genetically engineered a virus that is deadly to chickens and found that it can kill prostate cancer in vitro.

International collaboration doubles the number of genetic regions associated with breast, prostate, and ovarian cancers.

The journal PLOS Pathogens abruptly retracts the seminal paper linking XMRV to disease.

US Preventive Services Task Force recommends against a commonly used prostate cancer screening.

What researchers are learning as they sequence, map, and decode species’ genomes